Search for Clinical Trial Results

Sponsored By

Monoclonal Gammopathy of Undetermined Significance - 18 Studies Found

Status Study
Suspended Study Name: Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Condition:
  • Neuropathy
  • Nonmalignant Monoclonal Gammopathy of Undetermined Signific
    Date: 2008-04-22
    Interventions: Drug: Lenalidomide Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days res
Completed Study Name: Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Condition:
  • Smoldering Myeloma
  • Monoclonal Gammopathy of Undetermined Significance<
    Date: 2010-04-22
Recruiting Study Name: Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)
Condition: Monoclonal Gammopathy of Unknown Significance
Date: 2016-09-15
Interventions:
  • Other: Blood sample taken
  • Other: Answering
Completed Study Name: A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Condition:
  • Monoclonal Gammopathy of Undetermined Significance
  • Multiple Mye
    Date: 2010-09-23
    Interventions: Biological: Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of
Completed Study Name: Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy
Condition:
  • Monoclonal Gammopathy
  • Monoclonal Gammopat
    Date: 2011-08-23
    Interventions: Other: blood and bone marrow samples Specific tests of the
Active, not recruiting Study Name: Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
Condition:
  • Monoclonal Gammopathy of Undetermined Significance
  • Smoldering M
    Date: 2010-03-01
    Interventions: Genetic: Genetic study of DNA copies Gene expression profiling, DNA copy number variation
Recruiting Study Name: Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies
Condition:
  • Monoclonal Gammopathy of Unknown Significance
  • Smoldering Multip
    Date: 2016-03-30
    Interventions: Procedure: Blood Collection Blood (about 1-2 tablespoons) collected for biomarker and routine tests and
Terminated Study Name: Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
Condition: Precancerous Condition
Date: 2007-12-20
Interventions: Biological: Rituximab Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four
Not yet recruiting Study Name: Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
Condition:
  • Monoclonal Gammopathies
  • Overweight
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Drug: 18-NaF PET The patient w
Next >>>